Market Overview
Global Respiratory Syncytial Virus Fusion Protein Drug market size was valued at USD 1.73 billion in 2024. The market is projected to grow from USD 1.86 billion in 2025 to USD 3.17 billion by 2032, exhibiting a CAGR of 7.9% during the forecast period.
Respiratory Syncytial Virus (RSV) fusion protein drugs are a class of therapeutics designed to target the F-protein of the virus, which facilitates its entry into host cells. These drugs include monoclonal antibodies, therapeutic proteins, and vaccines, which play a crucial role in preventing and treating RSV infections—particularly in high-risk populations such as infants, elderly individuals, and immunocompromised patients.
USD 1.73 billion in 2024
2032 USD 3.17 billion by 2032
of 7.9%
Monoclonal Antibodies Segment Dominates the Market Due to High Therapeutic Efficacy and Targeted Action
Monoclonal Antibodies
Subtypes: Palivizumab, Nirsevimab, and others
Therapeutic Protein
Vaccine
Subtypes: Live-attenuated, Subunit, and others
The Respiratory Syncytial Virus Fusion Protein Drug market is segmented based on type into:
By Application
Hospitals Lead the Market Due to High Patient Inflow and Advanced Treatment Facilities
The market is segmented based on application into: Hospitals Clinics Others
Portable Neuromonitoring Device Market
Our Key Players
GlaxoSmithKline plc (UK)
Johnson & Johnson (U.S.)
Pfizer Inc. (U.S.)
Merck & Co., Inc. (U.S.)
Bavarian Nordic A/S (Denmark)
Novavax, Inc. (U.S.)
https://www.24lifesciences.com
